What is the difference between ARA-290 and Vesugen?

ARA-290: Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing Vesugen: Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls

Is ARA-290 FDA approved?

ARA-290 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

Is Vesugen FDA approved?

Vesugen is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

How is ARA-290 administered in research settings?

In research settings, ARA-290 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is Vesugen administered in research settings?

In research settings, Vesugen is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ARA-290 vs Vesugen

Peptide Comparison

ARA-290 vs Vesugen

Name: ARA-290 vs Vesugen — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are Longevity & Cellular peptides.

ARA-290

Cibinetide

LongevityInvestigationalResearch Only

Half-life: ~2 min (IV); ~10–20 min (SC)

16 providers listed

Full ARA-290 profile →

Vesugen

Lys-Glu-Asp

LongevityNot EvaluatedResearch Only

Half-life: Unknown

2 providers listed

Full Vesugen profile →

Bottom line

ARA-290 carries stronger published evidence (RCT, 3 key studies) than Vesugen (Review, 2); both are research compounds.

Quick Verdict

ARA-290

Evidence

Clinical

Half-life

~2 min (IV); ~10–20 min (SC)

Vesugen

Evidence

Review-level

Half-life

Unknown

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	ARA-290
Further along in FDA review	ARA-290
Oral administration option	Vesugen
Lower typical price per mg	Vesugen
More provider options (16 vs 2)	ARA-290

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

ARA-290

Vesugen

Mechanism Family

Longevity & Cellular

Half-life

~2 min (IV); ~10–20 min (SC)

Unknown

FDA Status

investigational

not evaluated

Admin Routes

subcutaneous, intravenous

subcutaneous, oral

Availability

Research Only

Providers

16 listed

2 listed

Avail. Notes

Non-hematopoietic EPO analog (cibinetide) by Araim Pharma. Phase 3 for sarcoidosis peripheral neuropathy; Dutch conditional marketing authorisation applied for. No FDA approval. Investigational.

Russian vascular peptide bioregulator (Lys-Glu-Asp) from Khavinson Institute. Developed for vascular endothelium health. Not FDA-approved. Not on any FDA list. Research chemical.

Research Evidence

ARA-290

ClinicalRCT · 3 key studies · most recent 2026

Vesugen

Review-levelReview · 2 key studies · most recent 2021

Research Citations

ARA-290

Cohort2026 · Neurobiol Dis

Immunometabolic dysregulation drives selective executive cognitive dysfunction in male db/db mice.

RCT2017 · Investigative Ophthalmology & Visual Science

Cibinetide (ARA 290) reduces small nerve fiber pathology in sarcoidosis patients

RCT2015 · Molecular Medicine

ARA 290, a non-hematopoietic erythropoietin analogue, improves metabolic control and neuropathic symptoms in…

Vesugen

Review2021 · Molecules

Peptide Regulation of Gene Expression: A Systematic Review

Review2020 · Stem Cell Reviews and Reports

Short Peptides in the Treatment of Age-Related Diseases

About ARA-290

Non-hematopoietic EPO analogue; activates innate repair receptor (IRR/EPOR/CD131 complex) without erythropoietic effects; promotes tissue repair and nerve healing

Research Areas

neuropathic pain relieftissue repairanti-inflammatorymetabolic improvement

About Vesugen

Tripeptide bioregulator targeting vascular endothelium; normalizes gene expression in smooth muscle and endothelial cells; reduces lipid accumulation in vessel walls

Research Areas

vascular repairendothelial functioncardiovascular anti-agingatherosclerosis reduction

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ARA-290

Reported (Unverified — Pending Clinical Review)

active erythrocytosis

No established clinical contraindications

Vesugen

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Price (per mg)

ARA-290

$4.18/mg

$3.38 – $5.00 range

26 vendors

View price index →Find providers →

Vesugen

$2.75/mg

$2.00 – $3.00 range

5 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ARA-290

16 listed

Browse directory →

Providers offering

Vesugen

2 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More Longevity & Cellular Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 22, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ARA-290 vs Vesugen — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/ara-290/vesugen

https://peptidebase.io/peptides/compare/ara-290/vesugen Methodology License Download JSON Download CSV